RESUMO
Expression of the neuropeptide galanin is markedly upregulated within the adult dorsal root ganglion (DRG) after peripheral nerve injury. We demonstrated previously that the rate of peripheral nerve regeneration is reduced in galanin knock-out mice, with similar deficits observed in neurite outgrowth from cultured mutant DRG neurons. Here, we show that the addition of galanin peptide significantly enhanced neurite outgrowth from wild-type sensory neurons and fully rescued the observed deficits in mutant cultures. Furthermore, neurite outgrowth in wild-type cultures was reduced to levels observed in the mutants by the addition of the galanin antagonist M35 [galanin(1-13)bradykinin(2-9)]. Study of the first galanin receptor (GalR1) knock-out animals demonstrated no differences in neurite outgrowth compared with wild-type animals. Similarly, use of a GalR1-specific antagonist had no effect on neuritogenesis. In contrast, use of a GalR2-specific agonist had equipotent effects on neuritogenesis to galanin peptide, and inhibition of PKC reduced neurite outgrowth from wild-type sensory neurons to that observed in galanin knock-out cultures. These results demonstrate that adult sensory neurons are dependent, in part, on galanin for neurite extension and that this crucial physiological process is mediated by activation of the GalR2 receptor in a PKC-dependent manner.
Assuntos
Bradicinina/análogos & derivados , Neuritos/metabolismo , Neurônios Aferentes/metabolismo , Receptores de Neuropeptídeos/metabolismo , Animais , Bradicinina/farmacologia , Células Cultivadas , Feminino , Galanina/antagonistas & inibidores , Galanina/genética , Galanina/farmacologia , Gânglios Espinais/citologia , Homozigoto , Camundongos , Camundongos Knockout , Camundongos Mutantes , Regeneração Nervosa/fisiologia , Neuritos/efeitos dos fármacos , Neurônios Aferentes/citologia , Neurônios Aferentes/efeitos dos fármacos , Fragmentos de Peptídeos/farmacologia , Proteína Quinase C/metabolismo , Receptores de Galanina , Receptores de Neuropeptídeos/antagonistas & inibidores , Receptores de Neuropeptídeos/genéticaRESUMO
The chimeric peptide M35 (galanin(1-3)-bradykinin(2-9)amide) is a high-affinity galanin receptor ligand which acts as a galanin receptor antagonist in many experimental models such as the flexor reflex and chronic constriction injury in rat. However, more recently there have been conflicting reports that M35 may act as a galanin receptor agonist in certain systems. Here we demonstrate that in the absence of endogenous galanin M35 has an agonistic effect, significantly enhancing neurite outgrowth from cultured adult mouse dorsal root ganglion neurons, albeit at a lower potency than galanin peptide itself. However, in the presence of galanin its agonistic activity is masked and thus it appears to act as a galanin receptor antagonist.